These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33240608)

  • 1. Acetate correlates with disability and immune response in multiple sclerosis.
    Pérez-Pérez S; Domínguez-Mozo MI; Alonso-Gómez A; Medina S; Villarrubia N; Fernández-Velasco JI; García-Martínez MÁ; García-Calvo E; Estévez H; Costa-Frossard L; Alvarez-Cermeño JC; Luque-Garcia JL; Arroyo R; Villar LM; Alvarez-Lafuente R
    PeerJ; 2020; 8():e10220. PubMed ID: 33240608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
    Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
    Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced peripheral blood regulatory B cell levels are not associated with the Expanded Disability Status Scale score in multiple sclerosis.
    Guo S; Chen Q; Liang X; Mu M; He J; Fang Q; Song C; Sang D
    J Int Med Res; 2018 Sep; 46(9):3970-3978. PubMed ID: 30025488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and diagnostic features of patients with familial multiple sclerosis.
    Andrijauskis D; Balnyte R; Keturkaite I; Vaitkus A
    Med Hypotheses; 2019 Oct; 131():109310. PubMed ID: 31443766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis].
    Makshakov GS; Nazarov VD; Totolyan NA; Lapin SV; Mazing AV; Emanuel VL; Krasnov VS; Shumilina MV; Skoromets AA; Evdoshenko EP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10. Vyp. 2):4-10. PubMed ID: 29359727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis.
    Nazarov V; Makshakov G; Kalinin I; Lapin S; Surkova E; Mikhailova L; Gilburd B; Skoromets A; Evdoshenko E
    Immunol Res; 2018 Dec; 66(6):761-767. PubMed ID: 30635824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Lipoprotein Profile Is Associated With Protective Effects of Oral Contraceptive Use on Multiple Sclerosis Severity: A Cross-Sectional Study.
    Sena A; Macedo A; Ferret-Sena V; Capela C; Pedrosa R
    Front Neurol; 2019; 10():60. PubMed ID: 30787904
    [No Abstract]   [Full Text] [Related]  

  • 11. The Multiple Sclerosis Severity Score: fluctuations and prognostic ability in a longitudinal cohort of patients with MS.
    Gross RH; Sillau SH; Miller AE; Farrell C; Krieger SC
    Mult Scler J Exp Transl Clin; 2019; 5(1):2055217319837254. PubMed ID: 30911402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis.
    Saresella M; Marventano I; Barone M; La Rosa F; Piancone F; Mendozzi L; d'Arma A; Rossi V; Pugnetti L; Roda G; Casagni E; Cas MD; Paroni R; Brigidi P; Turroni S; Clerici M
    Front Immunol; 2020; 11():1390. PubMed ID: 32733460
    [No Abstract]   [Full Text] [Related]  

  • 13. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion.
    Rotondi M; Batocchi AP; Coperchini F; Caggiula M; Zerbini F; Sideri R; Leporati P; Nociti V; Frisullo G; Mirabella M; Magri F; Oliviero A; Chiovato L
    Neuroimmunomodulation; 2013; 20(6):341-7. PubMed ID: 24008588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis.
    Bucova M; Majernikova B; Durmanova V; Cudrakova D; Gmitterova K; Lisa I; Klimova E; Kluckova K; Buc M
    Neurol Sci; 2020 Mar; 41(3):599-604. PubMed ID: 31728855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Dec; 32(12):1969-1974. PubMed ID: 27603119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telephone validation of an Urdu translated version of the extended disability severity scale in multiple sclerosis patients.
    Syed MJ; Shah Z; Awan S; Wasay M; Fredrikson S
    Mult Scler Relat Disord; 2021 Feb; 48():102684. PubMed ID: 33360265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.